Integral Health Asset Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Integral Health Asset Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-120,000	Closed	-$12.2M	–	97
2023 Q2	$12.2M	Buy	120,000 +49,000	+69%	+$4.64M	1.52%	24
2023 Q1	$6.46M	Sell	71,000 -14,000	-16%	-$822K	1.3%	34
2022 Q4	$3.23M	Buy	+85,000	New	+$2.93M	0.68%	49
2022 Q3	–	Sell	-104,369	Closed	-$3.17M	–	85
2022 Q2	$3.17M	Buy	104,369 +69,369	+198%	+$2.07M	0.65%	50
2022 Q1	$1.15M	Sell	35,000 -68,000	-66%	-$2.02M	0.3%	62
2021 Q4	$2.72M	Buy	103,000 +68,000	+194%	+$5.26M	0.75%	43
2021 Q3	$3.52M	Sell	35,000 -7,000	-17%	-$821K	1.01%	43
2021 Q2	$5.94M	Sell	42,000 -2,000	-5%	-$226K	1.64%	26
2021 Q1	$4.39M	Sell	44,000 -6,000	-12%	-$700K	1.25%	33
2020 Q4	$6.18M	Buy	50,000 +10,000	+25%	+$1.31M	1.84%	23
2020 Q3	$3.9M	Buy	+40,000	New	+$5M	1.19%	30

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Integral Health Asset Management's RETA Position: Q3 2023 in Review

Integral Health Asset Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 120,000 shares — an estimated $12.2M sold.

Integral Health Asset Management first reported a position in RETA in Q3 2020 and held it in 11 quarters. The position peaked at $12.2M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Integral Health Asset Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Integral Health Asset Management sold 120,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $12.2M.
Integral Health Asset Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2020 and held it in 11 quarters.
Integral Health Asset Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $12.2M in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Integral Health Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.